Erlich et al. “Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes” Genomics, vol. 22, p. 288-295, 1994.* |
Brindle et al., “Analysis of the butyrylcholinesterase Gene and Nearby Chromosome 3 Markers in Alzheimer Disease,” Hum. Mol. Genet. 7:933-935 (1998). |
Lehmann et al., “Synergy Between the Genes for Butyrylcholinesterase K Variant and Apolipoprotein E4 in Late-Onset Confirmed Alzheimer's Disease,” Hum. Mol. Genet. 6:1933-1936 (1997). |
Main et al., “Apolipoprotein E Genotyping Using the Polymerase Chain Reaction and Allele-Specific Oligonucleotide Primers,” J. Lipid. Res. 32:183-187 (1991). |
Richard et al., “APOE Genotyping and Response to Drug Treatment in Alzheimer's Disease,” Lancet 349:539 (1997). |
Singleton et al., “No Association Between the K Variant of the Butyrylcholinesterase Gene and Pathologically Confirmed Alzheimer's Disease,” Hum. Mol. Genet. 7:937-939 (1998). |
La Du et al., “Phenotypic and Molecular Biological Analysis of Human Butyrylcholinesterase Variants,” Clin. Biochem. 23:423-431 (1990). |
Ki et al “No Association between the genes for BCHE-K variant and apoE4 in Late-onset Alzheimer's disease” Am. J. of Medical Genetics, vol 88, No. 2, p. 113-115, Apr. 1999.* |
Hiltunen et al “BCHE-K vairnat and apoE4 genes do no act in synergy in Finnish late-onset Alzheimer's disease patients” Neuroscience Letters, vol 250, No. 1, p. 69-71, Jun. 1988.* |
Crawford et al “The BCHE gene is neither indepentdently nor synergistically associated with the late-onset AD in clinical and community-based populations” Neuroscience Letters, vol 249, No. 2-3, p. 115-118, Jun. 1998.* |
Soreq et al “Mutations in the impared expression in the ACHE and BCHE genes: neurological implications” Biomed and Pharmacother, vol 48, No. 5-6, p. 253-259, 1994.* |
Camps et al “Synthesis, in vistro pharmacology, and molecular modeling of very potent tacrine” J. Med. Chem, vol 42, No. 17, pp. 3227-3242, Aug. 1999.* |
McKenna et al “Novel tacrine analogues for potential use against Alzheimer's Disease” J. Med, Chem. vol 40, No. 22, p. 3516-3523, Oct. 1997.* |
Wang et al “Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain ACHe” Neuropharmacology, vol 10, No. 4, pp. 789-793, Mar. 1999.* |
Lowenstein-Lichtenstein Y. et al., “Genetic predisposition to adverse consequences of anti-cholinesterase ‘atipical’ BCHE carriers,” Nature Medicine 1(10):1082-1085 (1995). |
Ehrlich G. et al., Population diversity of point mutations in the human ACHE and BCHE genes predicts variable responses to anticholinesterase drugs, Adv. Behav. Biology 44:661-667 (1995). |